CO6190608A2 - Sal de potasio cristalina de analogos de lipoxina a4 - Google Patents
Sal de potasio cristalina de analogos de lipoxina a4Info
- Publication number
- CO6190608A2 CO6190608A2 CO09057912A CO09057912A CO6190608A2 CO 6190608 A2 CO6190608 A2 CO 6190608A2 CO 09057912 A CO09057912 A CO 09057912A CO 09057912 A CO09057912 A CO 09057912A CO 6190608 A2 CO6190608 A2 CO 6190608A2
- Authority
- CO
- Colombia
- Prior art keywords
- potassium salt
- lipoxine
- formula
- optionally substituted
- substituents selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
- C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
1.- Una sal de potasio cristalina de la fórmula (I):en donde: R1 es -O-, -S(O)t- (donde t es 0, 1 ó 2), o una cadena de alquileno lineal o ramificada; y R2 es arilo (opcionalmente sustituido con uno o varios sustituyentes seleccionados de alquilo, alcoxi, halo, ha- loalquilo y haloalcoxi) o aralquilo (opcionalmente sustituido con uno o varios sustituyentes seleccionados de alquilo, alcoxi, halo, haloalquilo y haloalcoxi) y en donde el compuesto de la fórmula (I) es un estereoisómero individual o cualquier mezcla de estereoisómeros. 2.- La sal de potasio cristalina de acuerdo con la reivindicación 1, en donde R1 es -O- y R2 es fenilo opcionalmente sustituido con uno o varios sustituyentes seleccionados de flúor, cloro y yodo. 3.- La sal de potasio cristalina de acuerdo con la reivindicación 2 que tiene la fórmula:como un estereoisómero individual o cualquier mezcla de estereoisómeros.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87283006P | 2006-12-04 | 2006-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6190608A2 true CO6190608A2 (es) | 2010-08-19 |
Family
ID=39076610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09057912A CO6190608A2 (es) | 2006-12-04 | 2009-06-04 | Sal de potasio cristalina de analogos de lipoxina a4 |
Country Status (29)
Country | Link |
---|---|
US (2) | US7906678B2 (es) |
EP (2) | EP2089350B1 (es) |
JP (1) | JP5410984B2 (es) |
KR (3) | KR20090101169A (es) |
CN (1) | CN101553456B (es) |
AR (1) | AR064116A1 (es) |
AU (1) | AU2007327765B2 (es) |
BR (1) | BRPI0719679A2 (es) |
CA (1) | CA2670791C (es) |
CL (1) | CL2007003468A1 (es) |
CO (1) | CO6190608A2 (es) |
CR (1) | CR10837A (es) |
DO (1) | DOP2009000130A (es) |
EA (1) | EA018615B1 (es) |
EC (1) | ECSP099380A (es) |
HK (1) | HK1135961A1 (es) |
IL (1) | IL198434A (es) |
MA (1) | MA31079B1 (es) |
MX (1) | MX2009005911A (es) |
MY (1) | MY147951A (es) |
NO (1) | NO20092528L (es) |
NZ (1) | NZ577338A (es) |
PE (2) | PE20081200A1 (es) |
SV (1) | SV2009003286A (es) |
TN (1) | TN2009000167A1 (es) |
TW (1) | TWI415833B (es) |
UY (1) | UY30755A1 (es) |
WO (1) | WO2008068041A1 (es) |
ZA (1) | ZA200904689B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2007003468A1 (es) * | 2006-12-04 | 2008-07-04 | Bayer Schering Pharma Ag | Sal de potasio cristalina de analogos de lipoxina a4; metodode sintesis; composicion farmaceutica; y uso en el tratamiento de trastornos inflamatorios o autoinmunes. |
US20090036530A1 (en) * | 2006-12-04 | 2009-02-05 | Bayer Schering Pharma Aktiengesellschaft | Crystalline acid of lipoxin A4 analogs and method of making |
EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
US8637449B2 (en) * | 2009-08-27 | 2014-01-28 | Merck Sharp & Dohme Corp. | Processes for preparing protease inhibitors of hepatitis C virus |
US10434080B2 (en) | 2013-02-21 | 2019-10-08 | Forsyth Dental Infirmary For Children | Methods for increasing oral osteogenesis using lipoxin A4 (LXA4) and its analogs |
US20180078519A1 (en) * | 2015-03-18 | 2018-03-22 | The Forsyth Institute | Methods for Stabilizing Atherosclerotic Plaques Using Lipoxins, Resolvins, and Analogs Thereof |
EP3795179A1 (en) | 2016-06-03 | 2021-03-24 | Thetis Pharmaceuticals LLC | Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation |
EP3576843A4 (en) | 2017-01-31 | 2020-11-11 | The Brigham and Women's Hospital, Inc. | ALX RECEIVER LIGANDS DEFINING A BIOCHEMICAL ENDOTYPE FOR INFLAMMATION-BASED DISEASES |
CN111875530A (zh) * | 2020-08-17 | 2020-11-03 | 浙江朗华制药有限公司 | 一种普拉西坦水合物晶体及其制备方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5650435A (en) | 1991-04-01 | 1997-07-22 | Madara; James L. | Modulation of inflammation related to columnar epithelia |
CA2164951C (en) | 1993-06-15 | 2004-02-10 | Charles N. Serhan | Lipoxin compounds |
US6048897A (en) | 1993-06-15 | 2000-04-11 | Brigham And Women's Hospital | Lipoxin compounds and their use in treating cell proliferative disorders |
US5441951A (en) | 1994-06-15 | 1995-08-15 | Brigham & Women's Hospital | Lipoxin compounds |
AU7215294A (en) | 1993-06-29 | 1995-01-24 | Brigham And Women's Hospital | Modulation of inflammation related to columnar epithelia |
US6008205A (en) | 1997-04-04 | 1999-12-28 | The Brigham & Women's Hospital, Inc. | Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses |
US6236978B1 (en) * | 1997-11-14 | 2001-05-22 | New York University | System and method for dynamic profiling of users in one-to-one applications |
US6006466A (en) * | 1998-08-20 | 1999-12-28 | Washecka; John | Concealed linear payout holder for fishing leader |
SE9900274D0 (sv) | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
DK1165066T3 (da) | 1999-03-18 | 2006-03-06 | Brigham & Womens Hospital | Anvendelse af lipoxin-forbindelser til inhibering af TNF-alfa-initieret neutrofil respons |
EP2236140A1 (en) | 1999-03-18 | 2010-10-06 | The Brigham and Women's Hospital, Inc. | Regulation of phospholipase D activity |
CA2675416A1 (en) | 1999-03-18 | 2000-09-21 | Brigham And Women's Hospital | Lipoxin compounds and their use |
PL356100A1 (en) | 1999-11-09 | 2004-06-14 | Alcon Inc. | Lipoxin a4 |
AU2001249329A1 (en) | 2000-03-20 | 2001-10-03 | Brigham And Women's Hospital | Lipoxin analogs and methods for the treatment of periodontal disease |
US6831186B2 (en) * | 2001-11-06 | 2004-12-14 | Schering Aktiengesellschft | Lipoxin A4 analogs |
JP2005516011A (ja) | 2001-12-13 | 2005-06-02 | ランバクシー ラボラトリーズ リミテッド | 結晶二水化セフニディールカリウム |
EP1487830A1 (en) | 2002-03-15 | 2004-12-22 | Dr. Reddy's Laboratories Ltd. | Novel crystalline form of 5-(4-((3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)methoxy)benzyl)thiazolidine-2,4-dione potassium salt |
DE602004029982D1 (de) | 2003-01-30 | 2010-12-23 | Lek Pharmaceuticals | Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren |
WO2006035291A1 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Crystalline forms of cefdinir potassium |
US7223718B2 (en) * | 2005-03-07 | 2007-05-29 | Falcon Lab Llc | Enhanced glyphosate herbicidal concentrates |
JP2008525531A (ja) | 2005-10-31 | 2008-07-17 | テバ ファーマシューティカル インダストリーズ リミティド | セフジニルカリウム塩の結晶形 |
CL2007003468A1 (es) * | 2006-12-04 | 2008-07-04 | Bayer Schering Pharma Ag | Sal de potasio cristalina de analogos de lipoxina a4; metodode sintesis; composicion farmaceutica; y uso en el tratamiento de trastornos inflamatorios o autoinmunes. |
-
2007
- 2007-12-03 CL CL200703468A patent/CL2007003468A1/es unknown
- 2007-12-03 PE PE2007001704A patent/PE20081200A1/es not_active Application Discontinuation
- 2007-12-03 UY UY30755A patent/UY30755A1/es not_active Application Discontinuation
- 2007-12-03 US US11/999,000 patent/US7906678B2/en active Active
- 2007-12-03 PE PE2012000006A patent/PE20120395A1/es not_active Application Discontinuation
- 2007-12-04 WO PCT/EP2007/010785 patent/WO2008068041A1/en active Application Filing
- 2007-12-04 KR KR1020097011427A patent/KR20090101169A/ko active Application Filing
- 2007-12-04 JP JP2009539669A patent/JP5410984B2/ja not_active Expired - Fee Related
- 2007-12-04 BR BRPI0719679-2A2A patent/BRPI0719679A2/pt not_active IP Right Cessation
- 2007-12-04 AU AU2007327765A patent/AU2007327765B2/en not_active Ceased
- 2007-12-04 KR KR1020167011173A patent/KR20160054030A/ko not_active Application Discontinuation
- 2007-12-04 EP EP07847057.2A patent/EP2089350B1/en active Active
- 2007-12-04 AR ARP070105403A patent/AR064116A1/es unknown
- 2007-12-04 MY MYPI20092224A patent/MY147951A/en unknown
- 2007-12-04 KR KR1020147030409A patent/KR20140135847A/ko not_active Application Discontinuation
- 2007-12-04 TW TW096146154A patent/TWI415833B/zh not_active IP Right Cessation
- 2007-12-04 CA CA2670791A patent/CA2670791C/en not_active Expired - Fee Related
- 2007-12-04 MX MX2009005911A patent/MX2009005911A/es active IP Right Grant
- 2007-12-04 CN CN2007800448571A patent/CN101553456B/zh not_active Expired - Fee Related
- 2007-12-04 EP EP18190069.7A patent/EP3489214A1/en not_active Withdrawn
- 2007-12-04 NZ NZ577338A patent/NZ577338A/en not_active IP Right Cessation
- 2007-12-04 EA EA200900732A patent/EA018615B1/ru not_active IP Right Cessation
-
2009
- 2009-04-28 IL IL198434A patent/IL198434A/en not_active IP Right Cessation
- 2009-04-29 TN TNP2009000167A patent/TN2009000167A1/fr unknown
- 2009-06-03 EC EC2009009380A patent/ECSP099380A/es unknown
- 2009-06-04 CR CR10837A patent/CR10837A/es unknown
- 2009-06-04 CO CO09057912A patent/CO6190608A2/es not_active Application Discontinuation
- 2009-06-04 DO DO2009000130A patent/DOP2009000130A/es unknown
- 2009-06-04 SV SV2009003286A patent/SV2009003286A/es unknown
- 2009-06-29 MA MA32056A patent/MA31079B1/fr unknown
- 2009-07-03 ZA ZA2009/04689A patent/ZA200904689B/en unknown
- 2009-07-03 NO NO20092528A patent/NO20092528L/no not_active Application Discontinuation
-
2010
- 2010-03-16 HK HK10102732.7A patent/HK1135961A1/xx not_active IP Right Cessation
-
2011
- 2011-02-07 US US13/022,139 patent/US8049035B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6190608A2 (es) | Sal de potasio cristalina de analogos de lipoxina a4 | |
CY1113716T1 (el) | Νεα μεθοδος συνθεσης της αγομελατινης | |
UY32606A (es) | Sulfonamidas nematocidas | |
CO6321248A2 (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
UY29388A1 (es) | Derivados del (1,5-difenil-h-pirazol-3-il)oxadiazol, su preparación y su aplicacion en terapéutica. | |
CR8475A (es) | Fenilalanina-amidas sustituidas por benzoilo | |
AR084362A1 (es) | Amidas de aminoindano que tienen una alta actividad fungicida y sus composiciones fitosanitarias | |
RS52870B (en) | INHIBITOR PROLIL HYDROXYLASE | |
ATE542798T1 (de) | Organische verbindungen | |
CY1112705T1 (el) | Συντηγμενες κυκλικες ενωσεις | |
CO6241076A2 (es) | Compuestos de benzamida y aplicaciones de los mismos | |
AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
CO5611128A2 (es) | Compuestos derivados de n-aril-2-oxazolidinona-5-carboxamida como agentes antibacteriales | |
EA200802380A1 (ru) | Совместные кристаллы пирролидинонов | |
CY1112829T1 (el) | Νεα μεθοδος συνθεσης για την αγομελατινη | |
ECSP088479A (es) | Derivados de oxadiazol | |
AR058445A1 (es) | Un aditivo mejorador de asfalto y un cemento asfaltico y mezcla asfaltica que contienen al aditivo | |
UY30387A1 (es) | Nuevos compuestos | |
ES2557477T3 (es) | Nuevos compuestos peptídicos cíclicos | |
CY1115094T1 (el) | Νεα μεθοδος για την συνθεση (7-μεθοξυ-1-ναφθυλ) ακετονιτριλιου και εφαρμογη στην συνθεση αγομελατινης | |
CR11463A (es) | Compuestos de piridilmetil-sulfonamida | |
PE20090703A1 (es) | Nuevo procedimiento de sintesis del ranelato de estroncio y de sus hidratos | |
EA200801365A1 (ru) | Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины | |
CO6251235A2 (es) | Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica | |
MX2009012338A (es) | Compuestos organicos de azufre y su uso para controlar artropodos dañinos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |